Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly

被引:39
|
作者
Tabrizian, Parissa [1 ]
Jibara, Ghalib [1 ]
Shrager, Brian [1 ]
Franssen, Bernardo [1 ]
Yang, Ming-Jim [1 ]
Sarpel, Umut [1 ]
Hiotis, Spiros [1 ]
Labow, Daniel [1 ]
机构
[1] Mt Sinai Sch Med, Dept Surg, Div Surg Oncol, New York, NY 10029 USA
来源
SURGICAL ONCOLOGY-OXFORD | 2013年 / 22卷 / 03期
关键词
Hyperthermic intraperitoneal chemotherapy; Cytoreductive surgery; Peritoneal carcinomatosis; Elderly; PERITONEAL SURFACE DISEASE; DIGESTIVE-TRACT CANCER; COLORECTAL ORIGIN; SYSTEMIC CHEMOTHERAPY; CARCINOMATOSIS; MALIGNANCY; MANAGEMENT; CHEMOHYPERTHERMIA; COMPLICATIONS; MORTALITY;
D O I
10.1016/j.suronc.2013.06.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) has gained acceptance in the treatment of peritoneal carcinomatosis (PC) with reported morbidity and mortality rates of 27-56% and 0-11% respectively. The safety and outcome of such major operation in the elderly remains unclear. We report our experience at a high volume tertiary center. Method: A total of 170 consecutive patients underwent CRS-HIPEC for peritoneal carcinomatosis between March 2007 and July 2012. Mitomycin C (88.8%) was administered intraperitoneally at 42 degrees C for 90 min. Patients were categorized into two groups according to the age at the time of surgery: Group 1 (<= 65 years-old) and Group 2 (>65 years-old). Differences between the groups were analyzed. Univariate and multivariate analyses were performed to identify variables associated with major morbidity. Results: Of the 170 patients, 35 were older than 65 years. The two most common tumor sites were colorectal and appendiceal cancer. The perioperative morbidity and mortality rates in the elderly were 18.8% and 8.6% respectively. Gender, tumor type, estimated blood loss >400 mL, intraoperative blood transfusion, operative time >6 h, bowel anastomosis, intraoperative PCI >16, and extent of cytoreduction (Delta PCI) were not associated with major morbidity in the older group (p > 0.05). At a median follow-up of 15.7 months (0.2-53.5 months), recurrence rate for colorectal/appendiceal PC at 1 year was 48.0% in Group 1 and 44.3% in Group 2 (p = NS). Median survival for the colorectal/appendiceal carcinomatosis patients in Group 1 (n = 81) was 29.79 (SE 4.7) months and in Group 2 (n = 20) was 21.2 (SE 3.0) months, (p = 0.06, NS). Conclusion: CRS-HIPEC procedures for peritoneal carcinomatosis in the elderly demonstrate comparable perioperative outcome in well-selected patients. Optimal cytoreduction was achieved in the majority of cases and survival was not significantly different from that of the younger group. (c) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [1] Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients
    Macri, Antonio
    Saladino, Edoardo
    Trimarchi, Giuseppe
    Bartolo, Vincenzo
    Rossitto, Maurizio
    Cannao, Antonio
    Rizzo, Antongiacomo
    Famulari, Ciro
    [J]. IN VIVO, 2011, 25 (04): : 687 - 690
  • [2] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly
    Tabrizian, P.
    Jibara, G.
    Shrager, B.
    Franssen, B.
    Yang, M.
    Sarpel, U.
    Hiotis, S.
    Labow, D.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S73 - S74
  • [3] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly is Safe and Effective
    Laks, Shachar
    Bilik, Alona
    Schtrechman, Gal
    Adileh, Mohammad
    Mor, Eyal
    Boursi, Ben
    Halpern, Naama
    Margalit, Ofer
    Shacham-Shmueli, Einat
    Nissan, Aviram
    Ben-Yaacov, Almog
    [J]. JOURNAL OF SURGICAL RESEARCH, 2022, 279 : 739 - 747
  • [4] Cytoreductive Surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Elderly
    Votanopoulos, K. I.
    Shen, P.
    Stewart, J. H.
    Russell, G.
    Levine, E. A.
    Newman, N. A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S100 - S101
  • [5] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Durnford, S.
    Boss, L.
    Bell, J.
    [J]. BJA EDUCATION, 2021, 21 (05) : 187 - 193
  • [6] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes
    Robella, Manuela
    Vaira, Marco
    Cinquegrana, Armando
    De Simone, Michele
    [J]. MINERVA CHIRURGICA, 2019, 74 (03) : 195 - 202
  • [7] Trends in Outcomes After Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
    Gani, Faiz
    Conca-Cheng, Alison M.
    Nettles, Brenda
    Ahuja, Nita
    Johnston, Fabian M.
    [J]. JOURNAL OF SURGICAL RESEARCH, 2019, 234 : 240 - 248
  • [8] Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Rebecca M. Dodson
    Michael Kuncewitch
    Konstantinos I. Votanopoulos
    Perry Shen
    Edward A. Levine
    [J]. Annals of Surgical Oncology, 2018, 25 : 2152 - 2158
  • [9] Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Dodson, Rebecca M.
    Kuncewitch, Michael
    Votanopoulos, Konstantinos I.
    Shen, Perry
    Levine, Edward A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (08) : 2152 - 2158
  • [10] Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes
    Mogal, Harveshp
    Chouliaras, Konstantinos
    Levine, Edward A.
    Shen, Perry
    Votanopoulos, Konstantinos I.
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (01) : 129 - 142